The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema
- Conditions
- Refractory Diabetic Macular Edema
- Interventions
- Drug: injection of bevacizumab
- Registration Number
- NCT03821168
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened .
Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years .
How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches.
In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 58
- Patient with refractory diabetic macular edema at least one month after third injection
- previous vitreoretinal surgery previous glaucoma surgery glaucomatous patient open heart surgery active proliferative diabetic retinopathy one eye patients vitreous hemorrhage
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description intravitreal injection of bevacizumab and erythropoietin injection of bevacizumab and erythropoietin erythropoietin: intravitreal injection of bevacizumab injection of bevacizumab bevacizumab:1.25 mg
- Primary Outcome Measures
Name Time Method best corrected visual acuity 1 month Snellen chart
- Secondary Outcome Measures
Name Time Method Optical coherence tomography 1 month Optical coherence tomography
Trial Locations
- Locations (1)
Ophthalmic Research Center
🇮🇷Tehran, Iran, Islamic Republic of